240 related articles for article (PubMed ID: 16299296)
21. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
Oaks EV; Turbyfill KR
Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
[TBL] [Abstract][Full Text] [Related]
22. Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG.
Kotloff KL; Noriega F; Losonsky GA; Sztein MB; Wasserman SS; Nataro JP; Levine MM
Infect Immun; 1996 Nov; 64(11):4542-8. PubMed ID: 8890204
[TBL] [Abstract][Full Text] [Related]
23. Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.
Riddle MS; Kaminski RW; Di Paolo C; Porter CK; Gutierrez RL; Clarkson KA; Weerts HE; Duplessis C; Castellano A; Alaimo C; Paolino K; Gormley R; Gambillara Fonck V
Clin Vaccine Immunol; 2016 Dec; 23(12):908-917. PubMed ID: 27581434
[TBL] [Abstract][Full Text] [Related]
24. Further characterization of Shigella sonnei live vaccine candidates WRSs2 and WRSs3-plasmid composition, invasion assays and Sereny reactions.
Bedford L; Fonseka S; Boren T; Ranallo RT; Suvarnapunya AE; Lee JE; Barnoy S; Venkatesan MM
Gut Microbes; 2011; 2(4):244-51. PubMed ID: 21983066
[No Abstract] [Full Text] [Related]
25. Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease.
Herrington DA; Van de Verg L; Formal SB; Hale TL; Tall BD; Cryz SJ; Tramont EC; Levine MM
Vaccine; 1990 Aug; 8(4):353-7. PubMed ID: 2204243
[TBL] [Abstract][Full Text] [Related]
26. Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe.
Launay O; Lewis DJM; Anemona A; Loulergue P; Leahy J; Sciré AS; Maugard A; Marchetti E; Zancan S; Huo Z; Rondini S; Marhaba R; Finco O; Martin LB; Auerbach J; Cohen D; Saul A; Gerke C; Podda A
EBioMedicine; 2017 Aug; 22():164-172. PubMed ID: 28735965
[TBL] [Abstract][Full Text] [Related]
27. [Tolerance and immunogenicity of an oral dose of CVD 103-HgR, a live attenuated Vibrio cholerae 01 strain: a double-blind study of Chilean adults].
Lagos R; Avendaño A; Horwitz I; Prado V; Ferreccio C; Sotomayor V; Losonsky G; Wasserman SS; Cryz S; Kaper JB
Rev Med Chil; 1993 Aug; 121(8):857-63. PubMed ID: 8296092
[TBL] [Abstract][Full Text] [Related]
28. Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in volunteers.
Li A; Pál T; Forsum U; Lindberg AA
Vaccine; 1992; 10(6):395-404. PubMed ID: 1598788
[TBL] [Abstract][Full Text] [Related]
29. Safety and colonization of two novel VirG(IcsA)-based live Shigella sonnei vaccine strains in rhesus macaques (Macaca mulatta).
Collins TA; Barnoy S; Baqar S; Ranallo RT; Nemelka KW; Venkatesan MM
Comp Med; 2008 Feb; 58(1):88-94. PubMed ID: 19793462
[TBL] [Abstract][Full Text] [Related]
30. Live-attenuated Shigella vaccines.
Venkatesan MM; Ranallo RT
Expert Rev Vaccines; 2006 Oct; 5(5):669-86. PubMed ID: 17181440
[TBL] [Abstract][Full Text] [Related]
31. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel.
Passwell JH; Harlev E; Ashkenazi S; Chu C; Miron D; Ramon R; Farzan N; Shiloach J; Bryla DA; Majadly F; Roberson R; Robbins JB; Schneerson R
Infect Immun; 2001 Mar; 69(3):1351-7. PubMed ID: 11179298
[TBL] [Abstract][Full Text] [Related]
32. Construction of a stable attenuated Shigella sonnei DeltavirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model.
Hartman AB; Venkatesan MM
Infect Immun; 1998 Sep; 66(9):4572-6. PubMed ID: 9712824
[TBL] [Abstract][Full Text] [Related]
33. Whole genome analysis to detect potential vaccine-induced changes on Shigella sonnei genome.
Behar A; Fookes MC; Goren S; Thomson NR; Cohen D
Vaccine; 2015 Jun; 33(26):2978-83. PubMed ID: 25936664
[TBL] [Abstract][Full Text] [Related]
34. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults.
Cohen D; Ashkenazi S; Green MS; Gdalevich M; Robin G; Slepon R; Yavzori M; Orr N; Block C; Ashkenazi I; Shemer J; Taylor DN; Hale TL; Sadoff JC; Pavliakova D; Schneerson R; Robbins JB
Lancet; 1997 Jan; 349(9046):155-9. PubMed ID: 9111538
[TBL] [Abstract][Full Text] [Related]
35. Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates.
Simon JK; Maciel M; Weld ED; Wahid R; Pasetti MF; Picking WL; Kotloff KL; Levine MM; Sztein MB
Clin Immunol; 2011 May; 139(2):185-92. PubMed ID: 21388888
[TBL] [Abstract][Full Text] [Related]
36. Two live attenuated Shigella flexneri 2a strains WRSf2G12 and WRSf2G15: a new combination of gene deletions for 2nd generation live attenuated vaccine candidates.
Ranallo RT; Fonseka S; Boren TL; Bedford LA; Kaminski RW; Thakkar S; Venkatesan MM
Vaccine; 2012 Jul; 30(34):5159-71. PubMed ID: 22658966
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers.
Kirkpatrick BD; McKenzie R; O'Neill JP; Larsson CJ; Bourgeois AL; Shimko J; Bentley M; Makin J; Chatfield S; Hindle Z; Fidler C; Robinson BE; Ventrone CH; Bansal N; Carpenter CM; Kutzko D; Hamlet S; LaPointe C; Taylor DN
Vaccine; 2006 Jan; 24(2):116-23. PubMed ID: 16140433
[TBL] [Abstract][Full Text] [Related]
38. Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine.
Venkatesan MM; Hartman AB; Newland JW; Ivanova VS; Hale TL; McDonough M; Butterton J
Infect Immun; 2002 Jun; 70(6):2950-8. PubMed ID: 12010984
[TBL] [Abstract][Full Text] [Related]
39. [Construction and characterization of a live attenuated Shigella flexneri 2a vaccine strain, sf301 Delta virG and dsbA33G].
Yang XF; Zhou L; Zheng J; Si LS; Wang YL
Wei Sheng Wu Xue Bao; 2005 Oct; 45(5):748-52. PubMed ID: 16342769
[TBL] [Abstract][Full Text] [Related]
40. Fusion of HPV L1 into Shigella surface IcsA: a new approach in developing live attenuated Shigella-HPV vaccine.
Xu D; Wang D; Yang X; Cao M; Yu J; Wang Y
Antiviral Res; 2014 Feb; 102():61-9. PubMed ID: 24333518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
